Tarsus Pharmaceuticals (TARS) Enterprise Value (2019 - 2026)

Tarsus Pharmaceuticals' Enterprise Value history runs 8 years deep, the most recent figure standing at -$102.2 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 74.95% year-over-year to -$102.2 million in Q1 2026; TTM through Mar 2026 was -$102.2 million, a 74.95% increase from a year earlier, with the FY2025 full-year figure at -$184.2 million, up 36.78% from the prior year.
• Enterprise Value grew to -$102.2 million in Q1 2026 per TARS's latest filing, from -$184.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$102.2 million in Q1 2026 and bottomed at -$407.9 million in Q1 2025.
• The 5-year median for Enterprise Value is -$245.4 million (2022), against an average of -$260.3 million.
• Across the five-year window, Enterprise Value plunged 81.55% in 2024 and surged 74.95% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$217.0 million in 2022, then declined by 4.8% to -$227.4 million in 2023, then decreased by 28.11% to -$291.4 million in 2024, then jumped by 36.78% to -$184.2 million in 2025, then soared by 44.52% to -$102.2 million in 2026.
• Per Business Quant, the three latest TARS Enterprise Value figures stand at -$102.2 million (Q1 2026), -$184.2 million (Q4 2025), and -$401.8 million (Q3 2025).